Hyperparathyroidism, Hypovitaminosis D, Postmenopausal Osteoporosis
Conditions
Keywords
Postmenopause, Postmenopausal Osteoporosis, Hypovitaminosis D, Hyperparathyroidism, Risedronate, Osteopenia, Bone Mineral Density, Bone resorption
Brief summary
Osteoporosis is defined as a systemic disease of bone mineralization, characterized by a decrease in bone mineral density that causes bone fragility and increases the risk of fractures during menopause. Recently, a high prevalence of hypovitaminosis D has been found worldwide, which could trigger a state of secondary hyperparathyroidism that can worsen the state of postmenopausal patients with osteoporosis. An open-label, clinical trial was conducted in Mexican women with postmenopausal osteopenia-osteoporosis to determine the efficacy of the combined treatment with risedronate and high-dose vitamin D in improving bone mineral density, hyperparathyroidism, and hypovitaminosis D.
Detailed description
Participants were selected from the climacteric clinic of the regional hospital 1ro de Octubre-Instituto de Seguridad y Servicios Sociales para Los Trabajadores del Estado (ISSSTE), Mexico. All participants voluntarily accepted to be part of the study and provided written informed consent.This study was approved by the institutional ethical committee of the hospital with registration number COFEPRIS 17 CI 09005135 with the internal registration number 118.2021. Every participant was clinically examined. Their metabolic state was assessed by considering height, weight, body mass index (BMI) and the percentage of Hb1Ac. 33 patients were included among 40 to 78 years with the diagnosis of postmenopausal osteoporosis with associated hyperparathyroidism, hypovitaminosis D or both conditions. All the patients were treated for 6 months with 35 mg of risedronate and 2800 IU of vitamin D once a week, with additional daily supplementation of 4000 IU of vitamin D. Statical analysis was performed using PAST 3.0 and GraphPad Prism 8.4.3. software. Some statical parameters, such as arithmetic median (µ), and standard deviation (S.D.) were calculated using Excel-Word. Graphics were constructed with GraphPad Prism 8.4.3 and tables were done in Excel-Word. The assigned α value for this study was \<0.05.
Interventions
DRUGRisedronate
Participants received risedronate 35 mg once a week for 6 months.
DRUGVitamin D
Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
Sponsors
National Polytechnic Institute, Mexico
Universidad Nacional Autonoma de Mexico
Hospital Regional 1o de Octubre
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
33 participants between 40 and 78 years old with a diagnosis of postmenopausal osteoporosis or osteopenia with associated hyperparathyroidism, hypovitaminosis or both conditions were selected. All participants were treated for 6 months with risedronate 35 mg and vitamin D 2800 IU once a week, with additional daily vitamin D supplementation of 4000 IU.
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 78 Years
Healthy volunteers
No
Inclusion criteria
* Participants with a diagnosis of postmenopausal osteoporosis or osteopenia. * Participants with a diagnosis of hyperparathyroidism or hypovitaminosis D. * Participants who accepted to participate and that provided informed consent.
Exclusion criteria
* Participants with oncological pathologies. * Participants with recent fractures. * Participants with gastric intolerance or hypersensitivity to the drugs. * Participants were under treatment with another antiresorptive or bone-forming drug, or if they were receiving treatment with thiazide diuretics, lithium, teriparatide or glucocorticoids. * Participants with Addison's disease, pheochromocytoma or depressive disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Remission of hyperparathyroidism | 6 months | Remission of hyperparathyroidism was considered when serum parathyroid hormone \[PTH\] values were below 45 pg/mL. |
| Remission of hypovitaminosis D | 6 months | Remission of hypovitaminosis D was considered when serum 25-hydroxy vitamin D \[25(OH)D\] was above 29 pg/ml. |
| Remission of osteopenia | 6 months | Osteopenia remission was considered when densitometry T-score values were below -1. |
| Remission of Osteoporosis | 6 months | Osteoporosis remission was considered when densitometry T-score values were below -2.4. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fracture Risk Assessment Tool (FRAX®) for hip fracture | 6 months | Fracture Risk Assessment Tool (FRAX®) for hip fracture was used to determine the 10-year probability of hip fracture. When the predicted risk was greater than 3% was considered a high risk for hip fracture, and when it was lower than 3%, it was considered a low risk for hip fracture. |
| Change from baseline serum calcium at 6 months | 6 months | Calcium was evaluated as a bone mineralization marker. |
| Fracture Risk Assessment Tool for major osteoporotic fracture (FRAX® Mo) | 6 months | Fracture Risk Assessment Tool for major osteoporotic fracture (FRAX® Mo) was used to determine the 10-year probability of major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture). When the predicted risk was greater than 20% was considered a high risk for major osteoporotic fracture, and when it was lower than 20%, it was considered a low risk of major osteoporotic fracture. |
| Change from baseline serum phosphorus at 6 months | 6 months | Phosphorus was evaluated as a bone mineralization marker. |
| Change from baseline urinary calcium at 6 months | 6 months | Urinary calcium was evaluated as an indirect marker of bone demineralization. |
| Change from bone resorption biomarker at 6 months | 6 months | Alkaline Phosphatase was evaluated as a bone resorption biomarker. |
Countries
Mexico
Outcome results
None listed